Home >Research Discovery>Discovery Biology
Introduction of group leader
Office phone: +82-2-3010-2368
Email: haengran.seo at ip-korea.org
Office location: R3.42 & Asan Medical Center
The Cancer Biology Research Laboratory’s (CBRL) area of expertise is liver cancer. Despite liver cancer being the sixth most frequent malignant tumor cancer globally (2012. CDC), and the second leading cause of cancer-related deaths (2012. CDC), it has been difficult to develop effective targeted therapies. There are only a few ways to treat liver cancer currently and only 10-20% of liver cancers can be removed surgically , therefore more innovative and novel approaches must be taken to improve treatment options.
To overcome the limitations of existing liver cancer therapies, CBRL takes a holistic view of tumors, constructing a 3-dimensional (3D) tumor microenvironment in vitro to fully understand tumor development, progression, chemo-resistance and treatment response which can be used as a platform for anti-cancer drug discovery, improving personalized cancer therapy.
Our present activity focuses on:
• Establishing 3D tumor microenvironment in vitro
• Investigating reciprocal crosstalk between the tumor and tumor microenvironment to reveal new information on infrastructure that supports tumor existence
• Examining new molecular mechanism(s) involved in anti-liver cancer drug resistance
• Establishing 3D tumor microenvironment platform for anti-liver cancer drug discovery
• Discovering new biomarker(s) for liver cancer early diagnosis and novel target(s) for liver cancer therapy
1) CDC : Centers for Disease Control and Prevention
2) Hepatocellular carcinoma. MedlinePlus, Medical Encyclopedia and wikipedia
Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma.
Song YH, Kim JS, Kim SH, Yu ES, Kim KH, Oh HB, Lee HC, Kim KM, Seo HR
J Exp Clin Cancer Res. 2018 May 25;37(1):109
TGF-β-independent CTGF induction regulates cell adhesion mediated drug resistance by increasing collagen I in HCC.
Song Y, Kim JS, Choi EK, Kim J, Kim KM, Seo HR
Oncotarget. 2017 Mar 28;8(13):21650-21662
Sulfasalazine attenuates evading anticancer response of CD133-positive hepatocellular carcinoma cells.
Song Y, Jang J, Shin TH, Bae SM, Kim JS, Kim KM, Myung SJ, Choi EK, Seo HR
J Exp Clin Cancer Res. 2017 Mar 3;36(1):38
CD133 confers cancer stem-like cell properties by stabilizing EGFR-AKT signaling in hepatocellular carcinoma.
Jang JW, Song Y, Kim SH, Kim JS, Kim KM, Choi EK, Kim J, Seo HR
Cancer Lett. 2017 Mar 28;389:1-10
Activated hepatic stellate cells play pivotal roles in hepatocellular carcinoma cell chemoresistance and migration in multicellular tumor spheroids.
Song Y, Kim SH, Kim KM, Choi EK, Kim J, Seo HR
Sci Rep. 2016 Nov 17;6:36750